drugset / Trial / NCT02545738

Antiproteinuric Effects of Liraglutide Treatment

NCT02545738

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.

Timeline

Start
2015-04
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous